摘要
目的探讨替雷利珠单抗联合含铂化疗作为新辅助治疗方案在非小细胞肺癌(NSCLC)患者中的疗效与安全性。方法回顾分析2023年1月-2024年12月我院收治的86例可切除NSCLC患者的临床资料,按治疗方案分为研究组(n=44)和对照组(n=42)。研究组采用替雷利珠单抗联合含铂化疗,对照组采用单纯含铂化疗,均治疗2-3个周期后行手术。比较两组影像学疗效、病理缓解率、不良反应发生率、围手术期指标及随访生存数据。结果研究组客观缓解率(ORR)、病理缓解率(MPR)均高于对照组(P<0.05)。两组疾病控制率(DCR)和病理完全缓解率(pCR)差异无统计学意义(P>0.05)。两组围手术期指标和不良反应发生率比较,差异无统计学意义(P>0.05)。随访显示,研究组无进展生存期(PFS)较对照组延长,总生存率差异无统计学意义(P>0.05)。结论替雷利珠单抗联合化疗用于NSCLC新辅助治疗,可提高影像学与病理缓解率,延长无进展生存时间,且安全性良好,具有较高的临床应用价值。
Objective To evaluate the efficacy and safety of tislelizumab plus platinum-based chemotherapy as neoadjuvant treatment in patients with non-small cell lung cancer(NSCLC).Methods A retrospective analysis was conducted on the clinical data of 86 resectable NSCLC patients treated at our hospital from January 2023 to December 2024. Patients were divided into a study group (n=44) and acontrol group (n=42) according to their treatment regimens. The study group received tislelizumab in combination with platinum-basedchemotherapy, while the control group received platinum-based chemotherapy alone. All patients underwent 2 to 3 treatment cyclesfollowed by surgical resection. Imaging response, pathological remission rate, adverse events incidence rate, perioperative indicators, andsurvival data were compared between the two groups. Results The study group had significantly higher objective response rate (ORR)and major pathological response (MPR) than the control group (P <0.05). There were no statistically significant differences between thetwo groups in terms of disease control rate (DCR) and pathological complete response (pCR) (P >0.05). There were also no significantdifferences in perioperative indicators or incidence of adverse events between the two groups (P >0.05). Follow-up data showed thatprogression-free survival (PFS) was longer in the study group, whereas no significant difference in overall survival (OS) was observedbetween the groups (P >0.05). Conclusion Tislelizumab combined with chemotherapy improves radiologic and pathological responsesand prolongs PFS in resectable NSCLC, with acceptable safety, indicating good clinical value.
作者
赵婷
曾燕
盛明
Zhao Ting;Zeng Yan;Sheng Ming(Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou 550001,China)
出处
《首都食品与医药》
2025年第18期58-61,共4页
Capital Food Medicine
关键词
非小细胞肺癌
新辅助治疗
替雷利珠单抗
化疗
免疫联合治疗
疗效
安全性
non-small cell lung cancer
neoadjuvant therapy
tislelizumab
chemotherapy
immunotherapy combination
efficacy
safety
